Screening Libraries

Product Data Sheet

ORM-10103

Cat. No.: HY-128678 CAS No.: 488847-28-5 Molecular Formula: $C_{20}H_{16}N_{2}O_{4}$ Molecular Weight: 348.35

Target: Na+/Ca2+ Exchanger

Pathway: Membrane Transporter/Ion Channel

Storage: Powder -20°C 3 years

> $4^{\circ}C$ 2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (717.67 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8707 mL	14.3534 mL	28.7068 mL
	5 mM	0.5741 mL	2.8707 mL	5.7414 mL
	10 mM	0.2871 mL	1.4353 mL	2.8707 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.97 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.97 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	ORM-10103 is a specific inhibitor of the Na+/Ca2+ exchanger (NCX), which decreases the NCX current with estimated IC ₅₀ s of 55 and 67 nM at -80 and at 20 mV, respectively $^{[1][2]}$.
IC ₅₀ & Target	IC50: 55 (NCX -80 mV), 67 nM (NCX 20 mV) ^[2]

REFERENCES

[1]. Jost N, et al. ORM-10103, a novel specific inhibitor of the Na+/Ca2+ exchanger, decreases early and delayed afterdepolarizations in the canine heart. Br J Pharmacol. 2013 Oct;170(4):768-78.

2]. Kohajda Z, et al. The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments. 2LoS One. 2016 Nov 10;11(11):e0166041.						
			dical applications. For research use only.			
	Tel: 609-228-6898	Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.com			
	Address. 1	Deer Park Dr., Suite Q., Morillio	utii Julictioli, NJ 00032, USA			

Page 2 of 2 www.MedChemExpress.com